With the development of the first GIP/GLP-1 co-agonist, tirzepatide, there has been an exponential increase in the effectiveness of incretin-mimetic pharmacological therapy for weight control in obese patients with and without diabetes
CBC (complete blood count): A quick health snapshot
Helmstdter J, Keppeler K, Kster L, Mnzel T, Daiber A, Steven S (2022) Glucagon- like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits-The role of the GLP-1 receptor
Individuals with T2D face an elevated risk of gastrointestinal complications, including paralytic ileus (PI) [8], characterized by impaired motor activity in the ileus without physical obstruction [9]
In recent years, there has been an increasing body of evidence to suggest that GLP-1s are an effective treatment as a weight-loss medication
By week 36, this weight loss effect was even more pronounced, increasing from 9.4% to 14.7%, while the placebo group saw a reduction of only 2.3%